Download our 2014 BIO.org International Meeting BROCHURE

BNOAT_for_BIO_6.pdf
546.7 KB

DOWNLOAD
 our
2014 BIO.org
International Meeting
PRESS RELEASE


BNOAT_press_release_051314.pdf
108.6 KB




BNOAT Oncology wins 2014 Buzz of Bio Contest
 
Technologies of Tomorrow

2014_Buzz_of_BIO_Winners.pdf
117.7 KB

BNOAT Oncology, Inc.

IN THE NEWS....

September 2014



BNOAT Oncology wins
the Buzz of Bio contest
 and will be presenting at
 the 2014 Bio Investor Forum
being held October 7-8
at
the Palace Hotel in San Francisco.



http://www.bio.org/bifbuzzofbio?utm_source=Highroads&utm_medium=email&utm_campaign=2014-09-04-BIF-Buzz-Winners&utm_term=Learn-More-BTN


 





June 2014:

Dr. Annette M. Sysel
 Vice President of BNOAT Oncology, Inc. 
presented to the
Business Forum
at the
 2014 BIO International Conference
on:
  Wednesday, June 25th
 at the
San Diego Convention Center.

Check out our Partnering Page:

https://mybio.org/event/member/123976


http://convention.bio.org/
 

Our thanks to the staff at BIO.org for an over-the-top,  exciting and successful networking event. 



May  2014:



ABOUT US:

BNOAT Oncology, Inc. is an oncology research and development company founded by renowned cancer researcher, Dr. Joseph A. Bauer, a Professional Staff  Alumnus of the Cleveland Clinic Taussig Cancer Center (ranked top 10 in the United States by US News & World Report).

The company has the exclusive license to develop nitrosylcobalamin (NO-Cbl), a vitamin B12-based, "Trojan Horse"- anti-tumor agent.

BNOAT Oncology, Inc. will advance the clinical development of NO-Cbl a tumor-targeting, non-toxic anti-cancer agent with the goal of significantly improving the standard of care in both cancer treatment and prevention worldwide in both humans and animals.

Extensive research as shown that NO-Cbl functions as a “Trojan Horse” by deceiving cancer cells into taking up a toxic payload and ultimately causing cell death. The Developmental Therapeutics Program (DTP) of the National Cancer Institute (NCI) independently validated the anti-tumor properties of NO-Cbl in 60 different human cancer cell lines.

The results of Dr. Bauer’s dog studies received international media attention and were featured in US News and World Report, Forbes, Web MD, MSNBC Health and Medicine, the American Chemical Society and in several local news programs and newspapers. NO-Cbl significantly reduced the size of the tumors (65% on average) in all of the dogs and in some dogs completely eliminated the tumor altogether. NO-Cbl increased the life span of each animal and improved its quality of life without the adverse side effects commonly associated with current chemo or radiation therapy regimes.

BNOAT Oncology, Inc. contract research labs produce kilogram quantities of cGMP NO-Cbl utilizing a specially trained, GMP manufacturing team that operates under the USFDA Guidelines for Bulk Pharmaceutical Chemicals (BPC), www.fda.gov, and is backed by a comprehensive documentation system.







Website Builder